Cytotoxicity of lanostane-type triterpenoids and ergosteroids isolated from Omphalia lapidescens on MDA-MB-231 and HGC-27 cells - 18/09/19
pages | 8 |
Iconographies | 8 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | Three triterpenoids and seven Δ22-ergosteroids were isolated from Omphalia lapidescens. |
• | Compound 1 possesses a new 24,25,26,27-tetranorlanostane carbon skeleton. |
• | The new ergosteroid 4 induced apoptosis in MDA-MB-231 and HGC-27 cells significantly. |
• | Compound 4 regulated the procaspase-3 expression and the Bax/Bcl-2 expression ratio. |
Abstract |
Omphalia lapidescens Schroet. is a medicinal macrofungus in China that has shown good antitumor activity in recent research. To explore the potential cytotoxic compounds from O. lapidescens, the ethyl acetate soluble fraction of a 95% ethanol extract with cytotoxic activity was phytochemically investigated. A new tetranorlanostane triterpenoid (1) and a new ergosteroid (4), together with two known lanostanes (2 and 3) and six known Δ22-ergosteroids (5−10), were isolated. Notably, compound 1 possesses a new 24,25,26,27-tetranorlanostane carbon skeleton. All isolates, except compound 8, were tested for cytotoxic activities using a human breast cancer cell line (MDA-MB-231) and a human gastric cancer cell line (HGC-27) in vitro. The new nortriterpenoid (1) exhibited no obvious cytotoxicity, while the known triterpenoid (3) showed significant cytotoxicity against MDA-MB-231 and HGC-27 cells. Compound 4 exhibited the highest cytotoxicity against MDA-MB-231 and HGC-27 cells, with IC50 values of 11.33 ± 2.18 and 12.28 ± 3.64 μM, respectively. Furthermore, Hoechst fluorescence 33342 staining and Western blot tests demonstrated that compound 4 induced apoptosis in MDA-MB-231 cells by downregulating procaspase-3 expression and upregulating the expression ratio of Bax/Bcl-2.
Le texte complet de cet article est disponible en PDF.Keywords : Omphalia lapidescens, Nortriterpenoid, Ergosteroid, Cytotoxic activity, MDA-MB-231, HGC-27
Plan
Vol 118
Article 109273- octobre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?